PMID- 37369499
OWN - NLM
STAT- MEDLINE
DCOM- 20230629
LR  - 20230717
IS  - 1791-7549 (Electronic)
IS  - 0258-851X (Print)
IS  - 0258-851X (Linking)
VI  - 37
IP  - 4
DP  - 2023 Jul-Aug
TI  - Evaluation of Clastogenic/Aneugenic Damage Using the FISH Micronucleus Assay in 
      Mice Exposed to Chromium (VI).
PG  - 1666-1671
LID - 10.21873/invivo.13252 [doi]
AB  - BACKGROUND/AIM: Exposure to chromium (VI) [Cr(VI)] has been postulated to be 
      associated with the induction of cancer. In vivo studies utilizing biomarkers of 
      genotoxic damage could aid in elucidating the mechanisms underlying the genotoxic 
      effects of Cr(VI) and their relationship with carcinogenesis. In this study, the 
      origin (clastogenic and/or aneugenic damage) and kinetics of micronuclei (MN) 
      induced by Cr(VI) were investigated. MATERIALS AND METHODS: Hsd:ICR female mice 
      were divided into groups of five individuals each. MN kinetics were measured in 
      groups treated with 20 or 25 mg/kg CrO(3) intraperitoneally using acridine 
      orange-coated slides in peripheral blood obtained from the caudal vein 0, 12, 24, 
      36, 48, 60, and 72 h after treatment. Whereas identification of MN with 
      centromeric DNA (MNK+) was measured at the dose of 20 mg/kg of CrO(3), using 
      fluorescence in situ hybridization (FISH) with a centromere-specific probe in 
      peripheral blood obtained at 0, 12, and 48 h after treatment. Control groups were 
      administered vehicle only. RESULTS: Total MN were quantified and the 
      clastogenic/aneugenic effects of Cr(VI) were evaluated based on the proportion of 
      MNK+ versus micronuclei without centromeric DNA (MNK-). There was a significant 
      increase in MN frequencies beginning at 12 h in the Cr(VI)-treated groups 
      demonstrating its genotoxicity. When calculating the MNK+ as a percentage of the 
      total MN, the increase was significant beginning 12 h after treatment. 
      CONCLUSION: The fact that the MNK+ and MNK- were observed at both evaluation 
      times corroborates Cr(VI) as a genotoxic agent and demonstrates that both 
      clastogenic and aneugenic damages are involved in the formation of MN.
CI  - Copyright (c) 2023, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Del Carmen Garcia-Rodriguez, Maria
AU  - Del Carmen Garcia-Rodriguez M
AD  - Laboratorio de Antimutagenesis, Anticarcinogenesis y Antiteratogenesis Ambiental, 
      Facultad de Estudios Superiores-Zaragoza, Universidad Nacional Autonoma de Mexico 
      (UNAM), Mexico City, Mexico; carmen.garcia@unam.mx.
FAU - Santiago-Moreno, Yolanda
AU  - Santiago-Moreno Y
AD  - Laboratorio de Antimutagenesis, Anticarcinogenesis y Antiteratogenesis Ambiental, 
      Facultad de Estudios Superiores-Zaragoza, Universidad Nacional Autonoma de Mexico 
      (UNAM), Mexico City, Mexico.
FAU - Molina-Alvarez, Bertha
AU  - Molina-Alvarez B
AD  - Laboratorio de Citogenetica, Departamento de Genetica Humana, Instituto Nacional 
      de Pediatria, Mexico City, Mexico.
FAU - Altamirano-Lozano, Mario
AU  - Altamirano-Lozano M
AD  - Laboratorio de Antimutagenesis, Anticarcinogenesis y Antiteratogenesis Ambiental, 
      Facultad de Estudios Superiores-Zaragoza, Universidad Nacional Autonoma de Mexico 
      (UNAM), Mexico City, Mexico.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - In Vivo
JT  - In vivo (Athens, Greece)
JID - 8806809
RN  - 0 (Mutagens)
RN  - 18540-29-9 (chromium hexavalent ion)
RN  - 0 (Aneugens)
RN  - 9007-49-2 (DNA)
SB  - IM
MH  - Female
MH  - Animals
MH  - Mice
MH  - *Mutagens
MH  - Micronucleus Tests
MH  - In Situ Hybridization, Fluorescence
MH  - *Aneugens
MH  - Mice, Inbred ICR
MH  - DNA Damage
MH  - DNA
PMC - PMC10347897
OTO - NOTNLM
OT  - Hexavalent chromium
OT  - aneugenic
OT  - clastogenic
OT  - fluorescence in situ hybridization analysis
OT  - micronucleus test
COIS- The Authors declare no conflicts of interest.
EDAT- 2023/06/28 01:06
MHDA- 2023/06/29 06:43
PMCR- 2023/07/03
CRDT- 2023/06/27 20:53
PHST- 2023/04/18 00:00 [received]
PHST- 2023/05/10 00:00 [revised]
PHST- 2023/05/19 00:00 [accepted]
PHST- 2023/06/29 06:43 [medline]
PHST- 2023/06/28 01:06 [pubmed]
PHST- 2023/06/27 20:53 [entrez]
PHST- 2023/07/03 00:00 [pmc-release]
AID - 37/4/1666 [pii]
AID - 10.21873/invivo.13252 [doi]
PST - ppublish
SO  - In Vivo. 2023 Jul-Aug;37(4):1666-1671. doi: 10.21873/invivo.13252.